Kombinationschemotherapie, Bevacizumab und/oder Atezolizumab bei der Behandlung von Patienten mit metastasierendem Darmkrebs mit mangelhafter DNA-Mismatch-Reparatur, die COMMIT-Studie
Darmkrebs-Metastasen-dMMR/MSI-H-Immuntherapie (COMMIT)-Studie: Eine randomisierte Phase-III-Studie zur mFOLFOX6/Bevacizumab/Atezolizumab-Kombination versus Atezolizumab-Einzelwirkstoff in der Erstlinienbehandlung von Patienten mit mangelhafter DNA-Mismatch-Reparatur (dMMR)/Mikrosatellit Instabilitätshoch (MSI-H) Metastasierter Darmkrebs
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
- Sonstiges: Quality-of-Life Assessment
- Biologisch: Bevacizumab
- Arzneimittel: Fluorouracil
- Verfahren: Magnetic Resonance Imaging
- Sonstiges: Questionnaire Administration
- Verfahren: Biospecimen Collection
- Arzneimittel: Atezolizumab
- Arzneimittel: Oxaliplatin
- Verfahren: Computed Tomography
- Arzneimittel: Leucovorin
- Verfahren: Positron Emission Tomography
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Kingman, Arizona, Vereinigte Staaten, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, Vereinigte Staaten, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim, California, Vereinigte Staaten, 92806
- Kaiser Permanente-Anaheim
-
Baldwin Park, California, Vereinigte Staaten, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, Vereinigte Staaten, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, Vereinigte Staaten, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, Vereinigte Staaten, 94520
- John Muir Medical Center-Concord
-
Fontana, California, Vereinigte Staaten, 92335
- Kaiser Permanente-Fontana
-
Harbor City, California, Vereinigte Staaten, 90710
- Kaiser Permanente South Bay
-
Irvine, California, Vereinigte Staaten, 92618
- Kaiser Permanente-Irvine
-
Los Angeles, California, Vereinigte Staaten, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, Vereinigte Staaten, 90034
- Kaiser Permanente West Los Angeles
-
Marysville, California, Vereinigte Staaten, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Vereinigte Staaten, 95355
- Memorial Medical Center
-
Ontario, California, Vereinigte Staaten, 91761
- Kaiser Permanente-Ontario
-
Orange, California, Vereinigte Staaten, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, Vereinigte Staaten, 92868
- Saint Joseph Hospital - Orange
-
Panorama City, California, Vereinigte Staaten, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, Vereinigte Staaten, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, Vereinigte Staaten, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Vereinigte Staaten, 95817
- University of California Davis Comprehensive Cancer Center
-
Salinas, California, Vereinigte Staaten, 93901
- Salinas Valley Memorial
-
San Diego, California, Vereinigte Staaten, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Vereinigte Staaten, 92108
- Kaiser Permanente-Rio San Diego
-
San Marcos, California, Vereinigte Staaten, 92078
- Kaiser Permanente-San Marcos
-
Walnut Creek, California, Vereinigte Staaten, 94598
- John Muir Medical Center-Walnut Creek
-
Whittier, California, Vereinigte Staaten, 90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills, California, Vereinigte Staaten, 91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, Vereinigte Staaten, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Vereinigte Staaten, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, Vereinigte Staaten, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Vereinigte Staaten, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Vereinigte Staaten, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Vereinigte Staaten, 80920
- Memorial Hospital North
-
Denver, Colorado, Vereinigte Staaten, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, Vereinigte Staaten, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, Vereinigte Staaten, 80204
- Denver Health Medical Center
-
Denver, Colorado, Vereinigte Staaten, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, Vereinigte Staaten, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, Vereinigte Staaten, 80210
- AdventHealth Porter
-
Englewood, Colorado, Vereinigte Staaten, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, Vereinigte Staaten, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, Vereinigte Staaten, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Vereinigte Staaten, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, Vereinigte Staaten, 80401
- National Jewish Health-Western Hematology Oncology
-
Greeley, Colorado, Vereinigte Staaten, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Vereinigte Staaten, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, Vereinigte Staaten, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, Vereinigte Staaten, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, Vereinigte Staaten, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Vereinigte Staaten, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, Vereinigte Staaten, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, Vereinigte Staaten, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, Vereinigte Staaten, 06810
- Danbury Hospital
-
Hartford, Connecticut, Vereinigte Staaten, 06102
- Hartford Hospital
-
Meriden, Connecticut, Vereinigte Staaten, 06451
- Midstate Medical Center
-
New Britain, Connecticut, Vereinigte Staaten, 06050
- The Hospital of Central Connecticut
-
Norwich, Connecticut, Vereinigte Staaten, 06360
- William Backus Hospital
-
-
Delaware
-
Millville, Delaware, Vereinigte Staaten, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Vereinigte Staaten, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Vereinigte Staaten, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Vereinigte Staaten, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, Vereinigte Staaten, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville, Florida, Vereinigte Staaten, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, Vereinigte Staaten, 32803
- AdventHealth Orlando
-
-
Georgia
-
Albany, Georgia, Vereinigte Staaten, 31701
- Phoebe Putney Memorial Hospital
-
Athens, Georgia, Vereinigte Staaten, 30607
- University Cancer and Blood Center LLC
-
Augusta, Georgia, Vereinigte Staaten, 30912
- Augusta University Medical Center
-
Augusta, Georgia, Vereinigte Staaten, 30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta, Georgia, Vereinigte Staaten, 30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan, Georgia, Vereinigte Staaten, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise, Idaho, Vereinigte Staaten, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, Vereinigte Staaten, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, Vereinigte Staaten, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Vereinigte Staaten, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Vereinigte Staaten, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Vereinigte Staaten, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, Vereinigte Staaten, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Vereinigte Staaten, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Vereinigte Staaten, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Vereinigte Staaten, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Vereinigte Staaten, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Vereinigte Staaten, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Vereinigte Staaten, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Vereinigte Staaten, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, Vereinigte Staaten, 61832
- Carle at The Riverfront
-
Decatur, Illinois, Vereinigte Staaten, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, Vereinigte Staaten, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Vereinigte Staaten, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, Vereinigte Staaten, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Vereinigte Staaten, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Vereinigte Staaten, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, Vereinigte Staaten, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, Vereinigte Staaten, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, Vereinigte Staaten, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Vereinigte Staaten, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, Vereinigte Staaten, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Vereinigte Staaten, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Vereinigte Staaten, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Vereinigte Staaten, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Vereinigte Staaten, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, Vereinigte Staaten, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Vereinigte Staaten, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Vereinigte Staaten, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Vereinigte Staaten, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Springfield Clinic
-
Urbana, Illinois, Vereinigte Staaten, 61801
- Carle Cancer Center
-
Washington, Illinois, Vereinigte Staaten, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Vereinigte Staaten, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Vereinigte Staaten, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Vereinigte Staaten, 46256
- Community Cancer Center North
-
Kokomo, Indiana, Vereinigte Staaten, 46904
- Community Howard Regional Health
-
Lafayette, Indiana, Vereinigte Staaten, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City, Indiana, Vereinigte Staaten, 46360
- Woodland Cancer Care Center
-
Mooresville, Indiana, Vereinigte Staaten, 46158
- Franciscan Health Mooresville
-
Terre Haute, Indiana, Vereinigte Staaten, 47804
- Union Hospital
-
-
Iowa
-
Ames, Iowa, Vereinigte Staaten, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Vereinigte Staaten, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, Vereinigte Staaten, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, Vereinigte Staaten, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Vereinigte Staaten, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Vereinigte Staaten, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Vereinigte Staaten, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Vereinigte Staaten, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, Vereinigte Staaten, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, Vereinigte Staaten, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Vereinigte Staaten, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, Vereinigte Staaten, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, Vereinigte Staaten, 67601
- HaysMed
-
Lawrence, Kansas, Vereinigte Staaten, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Vereinigte Staaten, 66061
- The University of Kansas Cancer Center - Olathe
-
Salina, Kansas, Vereinigte Staaten, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Vereinigte Staaten, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Vereinigte Staaten, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Vereinigte Staaten, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown, Kentucky, Vereinigte Staaten, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Vereinigte Staaten, 40503
- Baptist Health Lexington
-
Lexington, Kentucky, Vereinigte Staaten, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, Vereinigte Staaten, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, Vereinigte Staaten, 40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner, Louisiana, Vereinigte Staaten, 70065
- Ochsner Medical Center Kenner
-
New Orleans, Louisiana, Vereinigte Staaten, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta, Maine, Vereinigte Staaten, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, Vereinigte Staaten, 04401
- Eastern Maine Medical Center
-
Belfast, Maine, Vereinigte Staaten, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Vereinigte Staaten, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, Vereinigte Staaten, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, Vereinigte Staaten, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Vereinigte Staaten, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, Vereinigte Staaten, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton, Maryland, Vereinigte Staaten, 21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg, Maryland, Vereinigte Staaten, 20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo, Maryland, Vereinigte Staaten, 20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville, Maryland, Vereinigte Staaten, 21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, Vereinigte Staaten, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, Vereinigte Staaten, 48706
- McLaren Cancer Institute-Bay City
-
Bloomfield, Michigan, Vereinigte Staaten, 48302
- McLaren Cancer Institute-Bloomfield
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Vereinigte Staaten, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, Vereinigte Staaten, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Vereinigte Staaten, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Vereinigte Staaten, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, Vereinigte Staaten, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, Vereinigte Staaten, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Vereinigte Staaten, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Vereinigte Staaten, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Vereinigte Staaten, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, Vereinigte Staaten, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, Vereinigte Staaten, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, Vereinigte Staaten, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Vereinigte Staaten, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, Vereinigte Staaten, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, Vereinigte Staaten, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, Vereinigte Staaten, 48154
- Hope Cancer Clinic
-
Mount Clemens, Michigan, Vereinigte Staaten, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, Vereinigte Staaten, 48858
- McLaren Cancer Institute-Central Michigan
-
Novi, Michigan, Vereinigte Staaten, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, Vereinigte Staaten, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Vereinigte Staaten, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, Vereinigte Staaten, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, Vereinigte Staaten, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Vereinigte Staaten, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Vereinigte Staaten, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, Vereinigte Staaten, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, Vereinigte Staaten, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, Vereinigte Staaten, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, Vereinigte Staaten, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, Vereinigte Staaten, 55337
- Minnesota Oncology - Burnsville
-
Deer River, Minnesota, Vereinigte Staaten, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, Vereinigte Staaten, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, Vereinigte Staaten, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Vereinigte Staaten, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Vereinigte Staaten, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Vereinigte Staaten, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, Vereinigte Staaten, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Vereinigte Staaten, 55102
- United Hospital
-
Sandstone, Minnesota, Vereinigte Staaten, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, Vereinigte Staaten, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada, Mississippi, Vereinigte Staaten, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, Vereinigte Staaten, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, Vereinigte Staaten, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, Vereinigte Staaten, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, Vereinigte Staaten, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, Vereinigte Staaten, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, Vereinigte Staaten, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Freeman Health System
-
Joplin, Missouri, Vereinigte Staaten, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- University Health Truman Medical Center
-
St Louis, Missouri, Vereinigte Staaten, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, Vereinigte Staaten, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Vereinigte Staaten, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Vereinigte Staaten, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Great Falls Clinic
-
Great Falls, Montana, Vereinigte Staaten, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Vereinigte Staaten, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Vereinigte Staaten, 59901
- Logan Health Medical Center
-
Missoula, Montana, Vereinigte Staaten, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, Vereinigte Staaten, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Vereinigte Staaten, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, Vereinigte Staaten, 03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua, New Hampshire, Vereinigte Staaten, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton, New Jersey, Vereinigte Staaten, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, Vereinigte Staaten, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, Vereinigte Staaten, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, Vereinigte Staaten, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, Vereinigte Staaten, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, Vereinigte Staaten, 87110
- Presbyterian Kaseman Hospital
-
Las Cruces, New Mexico, Vereinigte Staaten, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, Vereinigte Staaten, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo, New York, Vereinigte Staaten, 14263
- Roswell Park Cancer Institute
-
Elmira, New York, Vereinigte Staaten, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success, New York, Vereinigte Staaten, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Vereinigte Staaten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Vereinigte Staaten, 14642
- University of Rochester
-
White Plains, New York, Vereinigte Staaten, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, Vereinigte Staaten, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, Vereinigte Staaten, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, Vereinigte Staaten, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville, North Carolina, Vereinigte Staaten, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Vereinigte Staaten, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, Vereinigte Staaten, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, Vereinigte Staaten, 28574
- ECU Health Oncology Richlands
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, Vereinigte Staaten, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Sanford Broadway Medical Center
-
Grand Forks, North Dakota, Vereinigte Staaten, 58201
- Altru Cancer Center
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44307
- Cleveland Clinic Akron General
-
Belpre, Ohio, Vereinigte Staaten, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Vereinigte Staaten, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Vereinigte Staaten, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Vereinigte Staaten, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Vereinigte Staaten, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Vereinigte Staaten, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Vereinigte Staaten, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Vereinigte Staaten, 43228
- Doctors Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Vereinigte Staaten, 43215
- Grant Medical Center
-
Columbus, Ohio, Vereinigte Staaten, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Vereinigte Staaten, 45409
- Miami Valley Hospital
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Vereinigte Staaten, 43015
- Grady Memorial Hospital
-
Kettering, Ohio, Vereinigte Staaten, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Vereinigte Staaten, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, Vereinigte Staaten, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield, Ohio, Vereinigte Staaten, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, Vereinigte Staaten, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Vereinigte Staaten, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Vereinigte Staaten, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, Vereinigte Staaten, 43050
- Knox Community Hospital
-
Newark, Ohio, Vereinigte Staaten, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, Vereinigte Staaten, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, Vereinigte Staaten, 44870
- North Coast Cancer Care
-
Sylvania, Ohio, Vereinigte Staaten, 43560
- ProMedica Flower Hospital
-
Warrensville Heights, Ohio, Vereinigte Staaten, 44122
- South Pointe Hospital
-
West Chester, Ohio, Vereinigte Staaten, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville, Ohio, Vereinigte Staaten, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, Vereinigte Staaten, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, Vereinigte Staaten, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Vereinigte Staaten, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, Vereinigte Staaten, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, Vereinigte Staaten, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Vereinigte Staaten, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Vereinigte Staaten, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, Vereinigte Staaten, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, Vereinigte Staaten, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Vereinigte Staaten, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, Vereinigte Staaten, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, Vereinigte Staaten, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, Vereinigte Staaten, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, Vereinigte Staaten, 16544
- Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Vereinigte Staaten, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills, Pennsylvania, Vereinigte Staaten, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, Vereinigte Staaten, 15146
- Forbes Hospital
-
Natrona Heights, Pennsylvania, Vereinigte Staaten, 15065
- Allegheny Valley Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, Vereinigte Staaten, 18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading, Pennsylvania, Vereinigte Staaten, 19611
- Reading Hospital
-
Wexford, Pennsylvania, Vereinigte Staaten, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, Vereinigte Staaten, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson, South Carolina, Vereinigte Staaten, 29621
- AnMed Health Cancer Center
-
Beaufort, South Carolina, Vereinigte Staaten, 29902
- Beaufort Memorial Hospital
-
Boiling Springs, South Carolina, Vereinigte Staaten, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, Vereinigte Staaten, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Vereinigte Staaten, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Vereinigte Staaten, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Saint Francis Hospital
-
Greer, South Carolina, Vereinigte Staaten, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Vereinigte Staaten, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, Vereinigte Staaten, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen, South Dakota, Vereinigte Staaten, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol, Tennessee, Vereinigte Staaten, 37620
- Bristol Regional Medical Center
-
Collierville, Tennessee, Vereinigte Staaten, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville, Tennessee, Vereinigte Staaten, 38501
- Cookeville Regional Medical Center
-
Johnson City, Tennessee, Vereinigte Staaten, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, Vereinigte Staaten, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis, Tennessee, Vereinigte Staaten, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo, Texas, Vereinigte Staaten, 79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont, Texas, Vereinigte Staaten, 77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe, Texas, Vereinigte Staaten, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, Vereinigte Staaten, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Vereinigte Staaten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg, Texas, Vereinigte Staaten, 78539
- STCC at DHR Health Institute for Research and Development
-
Houston, Texas, Vereinigte Staaten, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Vereinigte Staaten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Vereinigte Staaten, 77030
- Houston Methodist Hospital
-
Houston, Texas, Vereinigte Staaten, 77079
- UT MD Anderson - West Houston
-
League City, Texas, Vereinigte Staaten, 77573
- UT MD Anderson - League City
-
Port Arthur, Texas, Vereinigte Staaten, 77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land, Texas, Vereinigte Staaten, 77478
- UT MD Anderson - Sugar Land
-
Temple, Texas, Vereinigte Staaten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury, Vermont, Vereinigte Staaten, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol, Virginia, Vereinigte Staaten, 24201
- Ballad Health Cancer Care - Bristol
-
Burke, Virginia, Vereinigte Staaten, 22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville, Virginia, Vereinigte Staaten, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg, Virginia, Vereinigte Staaten, 24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean, Virginia, Vereinigte Staaten, 22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton, Virginia, Vereinigte Staaten, 24273
- Ballad Health Cancer Care - Norton
-
Richmond, Virginia, Vereinigte Staaten, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Vereinigte Staaten, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, Vereinigte Staaten, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, Vereinigte Staaten, 23970
- VCU Community Memorial Health Center
-
Woodbridge, Virginia, Vereinigte Staaten, 22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds, Washington, Vereinigte Staaten, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, Vereinigte Staaten, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, Vereinigte Staaten, 98368
- Jefferson Healthcare
-
Seattle, Washington, Vereinigte Staaten, 98122
- Swedish Medical Center-First Hill
-
Spokane, Washington, Vereinigte Staaten, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, Vereinigte Staaten, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston, West Virginia, Vereinigte Staaten, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Vereinigte Staaten, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo, Wisconsin, Vereinigte Staaten, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Vereinigte Staaten, 54911
- ThedaCare Regional Cancer Center
-
Appleton, Wisconsin, Vereinigte Staaten, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Vereinigte Staaten, 54806
- Duluth Clinic Ashland
-
Brookfield, Wisconsin, Vereinigte Staaten, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire, Wisconsin, Vereinigte Staaten, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, Vereinigte Staaten, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Bellin Memorial Hospital
-
Janesville, Wisconsin, Vereinigte Staaten, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek, Wisconsin, Vereinigte Staaten, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, Vereinigte Staaten, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, Vereinigte Staaten, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, Vereinigte Staaten, 54451
- Aspirus Medford Hospital
-
Minocqua, Wisconsin, Vereinigte Staaten, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Vereinigte Staaten, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Vereinigte Staaten, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Vereinigte Staaten, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, Vereinigte Staaten, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Vereinigte Staaten, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, Vereinigte Staaten, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, Vereinigte Staaten, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Vereinigte Staaten, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, Vereinigte Staaten, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, Vereinigte Staaten, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, Vereinigte Staaten, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Vereinigte Staaten, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne, Wyoming, Vereinigte Staaten, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, Vereinigte Staaten, 82414
- Billings Clinic-Cody
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo collection of blood samples
Andere Namen:
Given IV
Andere Namen:
Undergo CT or CT/PET
Andere Namen:
Given IV
Andere Namen:
Undergo CT/PET
Andere Namen:
|
|
Experimental: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo collection of blood samples
Andere Namen:
Given IV
Andere Namen:
Undergo CT or CT/PET
Andere Namen:
Undergo CT/PET
Andere Namen:
|
|
Experimental: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Ancillary studies Undergo collection of blood samples
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo CT or CT/PET
Andere Namen:
Given IV
Andere Namen:
Undergo CT/PET
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Progression free survival (PFS)
Zeitfenster: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
PFS-Rate
Zeitfenster: Mit 12 Monaten
|
Mit 12 Monaten
|
|
|
Overall survival (OS)
Zeitfenster: The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Zeitfenster: Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
Zeitfenster: Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
Zeitfenster: At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
Zeitfenster: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
Zeitfenster: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Severity of fatigue
Zeitfenster: At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
Zeitfenster: At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
Zeitfenster: Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Zeitfenster: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Zeitfenster: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
Zeitfenster: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
Zeitfenster: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Zeitfenster: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
Zeitfenster: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Zeitfenster: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
Zeitfenster: Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
Zeitfenster: Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Zeitfenster: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Caio Max S Rocha Lima, NRG Oncology
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Geschätzt)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach Standort
- Neubildungen
- Darmerkrankungen
- Gastrointestinale Neubildungen
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Magen-Darm-Erkrankungen
- Darmtumoren
- Rektale Erkrankungen
- Darmerkrankungen
- Kolorektale Neubildungen
- Aminosäuren, Peptide und Proteine
- Proteine
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Enzyme und Coenzyme
- Antikörper, monoklonal, humanisiert
- Antikörper, monoklonal
- Antikörper
- Immunglobuline
- Immunoproteine
- Blutproteine
- Serumglobuline
- Globuline
- Anorganische Chemikalien
- Koordinationskomplexe
- Pyrimidine
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Formyltetrahydrofolate
- Tetrahydrofolate
- Folsäure
- Pterins
- Pteridine
- Uracil
- Pyrimidinone
- Coenzyme
- Immunglobulinisotypen
- Sulfide
- Anionen
- Ionen
- Elektrolyte
- Schwefelwasserstoff
- Oxaliplatin
- Bevacizumab
- Fluoruracil
- Leucovorin
- Immunglobulin G
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Disulfide
- Atezolizumab
- Dehydroftorafur
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- NCI-2016-01961
- U10CA180868 (US NIH Stipendium/Vertrag)
- NCI-2016-01961 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (Andere Kennung: CTEP)
- NRG-GI004 (Andere Kennung: NRG Oncology)
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .